Daniel P Hawley1, Clare E Pain2, Eileen M Baildam2, Ruth Murphy2, Aileen E M Taylor2, Helen E Foster3. 1. Department of Paediatric Rheumatology, Sheffield Children's NHS Foundation Trust, Sheffield, Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, Department of Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, Department of Dermatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, and Department of Paediatric Rheumatology, Great North Children's Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. dhawley@doctors.org.uk. 2. Department of Paediatric Rheumatology, Sheffield Children's NHS Foundation Trust, Sheffield, Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, Department of Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, Department of Dermatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, and Department of Paediatric Rheumatology, Great North Children's Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 3. Department of Paediatric Rheumatology, Sheffield Children's NHS Foundation Trust, Sheffield, Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, Department of Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, Department of Dermatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, and Department of Paediatric Rheumatology, Great North Children's Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Department of Paediatric Rheumatology, Sheffield Children's NHS Foundation Trust, Sheffield, Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, Department of Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, Department of Dermatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, and Department of Paediatric Rheumatology, Great North Children's Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Abstract
OBJECTIVES: Juvenile localized scleroderma (JLS) is a rare condition that is often difficult to assess and for which a variety of monitoring tools have been described. We aimed to describe how monitoring tools are used and perceived by clinicians in the UK, to ascertain treatments used for JLS and to provide a description of transition arrangements to adult care. METHODS: An e-survey of UK paediatric rheumatologists and dermatologists managing children and young people (CYP) with JLS was distributed using the national organisations representing these clinician groups. We asked respondents for their views and experience using 15 JLS monitoring tools, about transition services and about treatments used. RESULTS: Thirty-five dermatologists and 13 paediatric rheumatologists responded. Paediatric rheumatologists managed more CYP with JLS than dermatologists (median 16-20 and 3, respectively). Transition arrangements were reported by 43% of dermatologists and 91% of paediatric rheumatologists. Medical photography was the most frequently regularly used monitoring tool (73% respondents). The modified Rodnan skin score was the skin score used most commonly: 33% of paediatric rheumatologists and 3% of dermatologists reported using this tool frequently. Topical treatments and ultraviolet light were used by 49-80% of dermatologists and 0-8% paediatric rheumatologists. Biologic drugs and CYC were used by 0-3% of dermatologists and 31-46% of paediatric rheumatologists. CONCLUSION: How monitoring tools are accessed, used and perceived by paediatric rheumatologists and dermatologists in the UK varies between and within clinician groups, as do treatment prescribing patterns and transition arrangements. These differences will impact on the feasibility of conducting multicentre clinical trials and on standardising clinical care.
OBJECTIVES:Juvenile localized scleroderma (JLS) is a rare condition that is often difficult to assess and for which a variety of monitoring tools have been described. We aimed to describe how monitoring tools are used and perceived by clinicians in the UK, to ascertain treatments used for JLS and to provide a description of transition arrangements to adult care. METHODS: An e-survey of UK paediatric rheumatologists and dermatologists managing children and young people (CYP) with JLS was distributed using the national organisations representing these clinician groups. We asked respondents for their views and experience using 15 JLS monitoring tools, about transition services and about treatments used. RESULTS: Thirty-five dermatologists and 13 paediatric rheumatologists responded. Paediatric rheumatologists managed more CYP with JLS than dermatologists (median 16-20 and 3, respectively). Transition arrangements were reported by 43% of dermatologists and 91% of paediatric rheumatologists. Medical photography was the most frequently regularly used monitoring tool (73% respondents). The modified Rodnan skin score was the skin score used most commonly: 33% of paediatric rheumatologists and 3% of dermatologists reported using this tool frequently. Topical treatments and ultraviolet light were used by 49-80% of dermatologists and 0-8% paediatric rheumatologists. Biologic drugs and CYC were used by 0-3% of dermatologists and 31-46% of paediatric rheumatologists. CONCLUSION: How monitoring tools are accessed, used and perceived by paediatric rheumatologists and dermatologists in the UK varies between and within clinician groups, as do treatment prescribing patterns and transition arrangements. These differences will impact on the feasibility of conducting multicentre clinical trials and on standardising clinical care.
Authors: Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok Journal: Eur J Pediatr Date: 2018-05-04 Impact factor: 3.183
Authors: Jorre S Mertens; Marieke M B Seyger; Rogier M Thurlings; Timothy R D J Radstake; Elke M G J de Jong Journal: Am J Clin Dermatol Date: 2017-08 Impact factor: 7.403
Authors: Helen E Foster; Christiaan Scott; Carl J Tiderius; Matthew B Dobbs Journal: Best Pract Res Clin Rheumatol Date: 2020-07-26 Impact factor: 4.098
Authors: Ming Keat Sng; Jeremy Soon Kiat Chan; Ziqiang Teo; Terri Phua; Eddie Han Pin Tan; Jonathan Wei Kiat Wee; Nikki Jun Ning Koh; Chek Kun Tan; Jia Peng Chen; Mintu Pal; Benny Meng Kiat Tong; Ya Lin Tnay; Xuan Rui Ng; Pengcheng Zhu; Shunsuke Chiba; Xiaomeng Wang; Walter Wahli; Nguan Soon Tan Journal: Cell Discov Date: 2018-04-03 Impact factor: 10.849
Authors: Mohammad Shahidi-Dadras; Fahimeh Abdollahimajd; Razieh Jahangard; Ali Javinani; Amir Ashraf-Ganjouei; Parviz Toossi Journal: Dermatol Res Pract Date: 2018-07-02